Injection site necrosis, atrophy with IM medroxyprogesterone
- PDF / 113,481 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 163 Views
1
Injection site necrosis, atrophy with IM medroxyprogesterone The Singapore Health Sciences Authority (HSA) is working with Pfizer to strengthen warnings on the packaging of Depo-Provera [medroxyprogesterone] to include injection site necrosis and skin atrophy as potential injection site reactions. While the HSA has not received any reports of injection site reactions associated with the intramuscular use of medroxyprogesterone, 103 medically confirmed cases have been reported globally since 31 July 2012. These cases have described events such as injection site skin atrophy, lipoatrophy, fat necrosis, muscle necrosis and injection site ulcer. Almost one third of these cases (30.1%) were considered serious. Overall, approximately 20% involved incorrect administration of the drug into the thigh, rather than the deltoid or gluteal region, and 10% involved other errors in administration; the drug’s role in the development of these adverse events could not be ruled out in 25% of cases. HSA - Health Sciences Authority. Intramuscular medroxyprogesterone and injection site necrosis and atrophy. Adverse Drug Reaction News 15: 2, No. 1, 1 803085939 Apr 2013. Available from: URL: http://www.hsa.gov.sg
0114-9954/10/1448-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 20 Apr 2013 No. 1448
Data Loading...
